Perseus Proteomics (TSE:4882) ROCE %: -47.24% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4882 Perseus Proteomics Inc TSE:4882
56 GF Score
Price 円160.00
GF Value 円439.72
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Perseus Proteomics ROCE %?

Perseus Proteomics TSE:4882 +2.56% 56 ROCE % is -47.24% as of Mar. 2026. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Perseus Proteomics's annualized ROCE % for the quarter that ended in Mar. 2026 was -47.24%.

Perseus Proteomics  (TSE:4882) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Perseus Proteomics ROCE % Related Terms

Perseus Proteomics ROCE % Historical Data

* Premium members only.

The historical data trend for Perseus Proteomics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perseus Proteomics ROCE % Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only -22.30 -24.89 -44.51 -50.72 -45.81

Perseus Proteomics Semi-Annual Data
Mar18 Mar19 Mar20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.11 -45.80 -43.96 -52.28 -47.24
TSE:4882
56GF Score
Perseus Proteomics Inc TSE:4882
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perseus Proteomics ROCE % Calculation

Perseus Proteomics's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-744.956/( ( (1818.837 - 124.866) + (1623.541 - 65.441) )/ 2 )
=-744.956/( (1693.971+1558.1)/ 2 )
=-744.956/1626.0355
=-45.81 %

Perseus Proteomics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=-690.38/( ( (1461.875 - 97.299) + (1623.541 - 65.441) )/ 2 )
=-690.38/( ( 1364.576 + 1558.1 )/ 2 )
=-690.38/1461.338
=-47.24 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.24% mean?
Perseus Proteomics (TSE:4882) has a ROCE % of -47.24% as of Mar. 2026.
Is Perseus Proteomics' ROCE % too high?
Perseus Proteomics' current ROCE % is -47.24%. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' ROCE % compare to LLY and JNJ?
Perseus Proteomics' ROCE % of -47.24% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current ROCE % is -47.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current ROCE % is -47.24%. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current ROCE % is -47.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Perseus Proteomics (TSE:4882) Overvalued in 2026?

Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued. The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72. GuruFocus considers Perseus Proteomics to be Significantly Undervalued.

Key valuation signals for TSE:4882:

  • ROCE %: -47.24%
  • GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
  • GF Score™: 56/100 with 1 warning sign

No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Perseus Proteomics Business Description

Address 30-1 Hakozakicho, Nihonbashi, Chuo-ku, AiNihombashi EAST 3rd floor, Tokyo, JPN, 103-0015
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score

Get the complete analysis for TSE:4882

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円160.00
Price
円439.72
GF Value